Bethan Psaila

A first-in-class CAR T-cell therapy targeting mutant calreticulin selectively depletes malignant stem cells in vivo and in fibrotic human organoids.

This study identifies LIN28B as essential for fetal B-lymphopoiesis and KMT2A::AFF1 infant leukemia initiation, showing its role in promoting proliferation and leukemogenesis.

This study identifies that HIF-1 activation by PIM1 in JAK2V617F-MPNs drives non-canonical transcription complex formation and disease progression.

This study uses spatial transcriptomic analysis and machine learning to redefine the topology of human bone marrow in health and myeloproliferative neoplasms, revealing new insights into cellular heterogeneity and fibrosis.

This study uses CRISPR-Cas genome editing to selectively inactivate JAK2 V617F mutations in patient cells, showing that heterozygous cells are not oncogene addicted while homozygous cells are eradicated, suggesting genome editing as a potential treatment for MPNs.

The paper identifies chromothripsis-induced amplification of DYRK1A in blast phase MPN as a driver of aggressive disease and a potential therapeutic target.

This paper introduces comBOs, a new human bone and lympho-myeloid bone marrow organoid model that includes multiple cell types and improves upon existing models for studying haematopoietic disorders.

This study identifies site- and stage-specific transitions in gene regulatory networks and lineage specification in human hematopoietic stem and progenitor cells across developmental stages.

This study introduces TARGET-seq, a method that simultaneously detects mutations and performs RNA-sequencing in single cells, revealing transcriptional and genetic tumor heterogeneity in myeloproliferative neoplasm cells.